TRGNF News and Press, Transgene S.A.

2026-06-29 16:12:09 ET Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC June 29, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: Transgene SA (TRGNF) Discusses P...

TG-MVA TM uses a scalable cell line manufacturing process intended to strengthen and diversify global mpox and smallpox vaccine supply TG-MVA TM demonstrated efficacy, immunogenicity and safety comparable to those of the approved reference vaccine against mpox in multiple preclinical models ...

Combining cutting-edge proprietary technologies and enhanced manufacturing, TG4070 is positioned as a novel vaccine relevant to multiple tumor types TG4070, the second candidate from the myvac ® platform: Full internalized AI-driven capabilities with SNIPER, a novel neoantigen predict...

TG-MVA builds on Transgene’s expertise in MVA (Modified Vaccinia Ankara) viral vectors, which are well established in smallpox vaccines development Extensive data with TG-MVA CEF and TG-MVA CL demonstrate protection against Monkeypox virus (MPXV) infections across several models ...

Strasbourg, France, May 22, 2026, 5:45 p.m. CET – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 22, 2026) at 11:00 a.m. CET at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d...

Strasbourg, France, May 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) , a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary...

Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per plan Phase 1 data from TG4050 in head and neck cancer published on medRxiv License agreement signed with NEC Bio to advance clinical developmen...

Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG ), a biotech company that designs and develops virus-based immunotherapies for the treatment o...

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority ( Autorité des march&...

Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC ...